Form 4: Zivo Bioscience Insider Acquires 34,000 Shares in Exchange Agreement

Mark E. Strome, a director and significant shareholder of Zivo Bioscience, acquired 34,000 shares through an exchange agreement, increasing his indirect holdings to 432,683 shares.

Summary

• Mark E. Strome, a director and 10% owner of Zivo Bioscience, acquired 34,000 shares of common stock.
• The shares were acquired indirectly through Strome Mezzanine Fund, LP (SMF).
• The acquisition was part of an exchange agreement where SMF cancelled a previous License Co-Development Participation Agreement with Zivo Bioscience.
• The price per share was $18.50.
• Following the transaction, Mr. Strome's indirect beneficial ownership increased to 432,683 shares.
• Strome Investment Management, LP and Strome Group, Inc. are also considered to have beneficial ownership due to their relationship with SMF and Mr. Strome.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of an insider transaction. It is neither particularly positive nor negative, but the insider's increased stake could be seen as a slightly positive signal.

Positives

• The acquisition of shares by a director and significant shareholder could be seen as a positive sign of confidence in the company's future.

Risks

• The document does not explicitly state any risks, but the cancellation of the License Co-Development Participation Agreement could have implications for future collaborations.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, and this filing is consistent with those requirements.
• The transaction is a private agreement between the company and a shareholder, which is not uncommon, but the details of the cancelled agreement are not disclosed, making direct comparison difficult.

Related Party Transactions

• The transaction is between Zivo Bioscience and Strome Mezzanine Fund, LP, which is related to Mark E. Strome, a director and significant shareholder.

Stakeholder Impact

• The increased shareholding by a director could be viewed positively by shareholders, indicating confidence in the company's prospects.

Key Dates

Keywords

Zivo Bioscience, Insider Trading, Share Acquisition, Form 4, Beneficial Ownership, Exchange Agreement, Strome, Director, 10% Owner